BioCentury | Dec 7, 2020
Politics, Policy & Law

Obamacare advocate Becerra likely to focus on expanding Affordable Care Act, drug pricing as HHS chief

...of the COVID-19 Response and counselor to the president. Walensky, chief of infectious diseases at Massachusetts General Hospital...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...—as well as manufacturing partnerships with Massachusetts General Hospital...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...Oncology R&D] Mark Cobbold from Harvard and Massachusetts General Hospital...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...also director of clinical research at the Massachusetts General Hospital...
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...ill hospitalized COVID-19 patients, according to a Massachusetts General Hospital...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

...al. Cell Rep.; published online Sept. 15, 2020doi:10.1016/j.celrep.2020.108150CONTACT: Andrew D. Luster, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.email: aluster@mgh.harvard.edu Claire Quang Massachusetts General Hospital Harvard...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...trial. The trial is being run by Massachusetts General Hospital...
BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...Inc. (NASDAQ:TYME) said it is collaborating with Massachusetts General Hospital...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...structural-based drug design, deep translational research capabilities, and collaborations with academic medical centers such as Massachusetts General Hospital...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...for $110,000 plus undisclosed milestones and royalties. Portable image-based cancer diagnostic A team led by Massachusetts General Hospital...
...Brand), BAY 80-6946 (Compound #), copanlisib (Generic) University of Iowa Kansas State University Cocrystal Pharma Inc. Tarveda Therapeutics Inc. Bayer AG Massachusetts General Hospital University...
Items per page:
1 - 10 of 678
BioCentury | Dec 7, 2020
Politics, Policy & Law

Obamacare advocate Becerra likely to focus on expanding Affordable Care Act, drug pricing as HHS chief

...of the COVID-19 Response and counselor to the president. Walensky, chief of infectious diseases at Massachusetts General Hospital...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...—as well as manufacturing partnerships with Massachusetts General Hospital...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...Oncology R&D] Mark Cobbold from Harvard and Massachusetts General Hospital...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...also director of clinical research at the Massachusetts General Hospital...
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...ill hospitalized COVID-19 patients, according to a Massachusetts General Hospital...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

...al. Cell Rep.; published online Sept. 15, 2020doi:10.1016/j.celrep.2020.108150CONTACT: Andrew D. Luster, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.email: aluster@mgh.harvard.edu Claire Quang Massachusetts General Hospital Harvard...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...trial. The trial is being run by Massachusetts General Hospital...
BioCentury | Aug 27, 2020
Product Development

COVID-19 Quick Takes: FDA authorizes 15-minute, $5 antigen test from Abbott; plus  updates from IDSA, CEPI, Novavax, VBI, Verndari, AZ, Fluidigm, Tyme

...Inc. (NASDAQ:TYME) said it is collaborating with Massachusetts General Hospital...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...structural-based drug design, deep translational research capabilities, and collaborations with academic medical centers such as Massachusetts General Hospital...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...for $110,000 plus undisclosed milestones and royalties. Portable image-based cancer diagnostic A team led by Massachusetts General Hospital...
...Brand), BAY 80-6946 (Compound #), copanlisib (Generic) University of Iowa Kansas State University Cocrystal Pharma Inc. Tarveda Therapeutics Inc. Bayer AG Massachusetts General Hospital University...
Items per page:
1 - 10 of 678